Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy

Zijian Li, Yue You, Noreen Griffin, Juan Feng, Fengping Shan

10.1016/j.intimp.2018.05.020

Highlights

LDN could broadly stimulate immune cells by blocking the binding of endogenous opioids and opioid receptors.•

LDN could broadly stimulate immune cells by blocking the binding of endogenous opioids and opioid receptors.•

LDN will play an important role in inflammation, autoimmune diseases and cancer.